MX2021015057A - Anticuerpos anti-talen y usos de los mismos. - Google Patents
Anticuerpos anti-talen y usos de los mismos.Info
- Publication number
- MX2021015057A MX2021015057A MX2021015057A MX2021015057A MX2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A
- Authority
- MX
- Mexico
- Prior art keywords
- talen
- antibodies
- things
- sample
- detecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861214P | 2019-06-13 | 2019-06-13 | |
| PCT/US2020/037589 WO2020252381A2 (en) | 2019-06-13 | 2020-06-12 | Anti-talen antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015057A true MX2021015057A (es) | 2022-01-18 |
Family
ID=73745889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015057A MX2021015057A (es) | 2019-06-13 | 2020-06-12 | Anticuerpos anti-talen y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11781248B2 (enExample) |
| EP (1) | EP3983435A4 (enExample) |
| JP (1) | JP7580406B2 (enExample) |
| KR (1) | KR102993101B1 (enExample) |
| CN (1) | CN113993891A (enExample) |
| AU (1) | AU2020291939B2 (enExample) |
| BR (1) | BR112021025029A2 (enExample) |
| CA (1) | CA3138501A1 (enExample) |
| IL (1) | IL288807B1 (enExample) |
| MX (1) | MX2021015057A (enExample) |
| SG (1) | SG11202112553WA (enExample) |
| WO (1) | WO2020252381A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4008347B1 (en) * | 2019-08-01 | 2025-04-30 | Mie University | GD2-BINDING MOLECULE |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| AU2008219972A1 (en) * | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient |
| KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| US20110200595A1 (en) * | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
| WO2013091903A1 (en) | 2011-12-22 | 2013-06-27 | Novo Nordisk A/S | Anti-crac channel antibodies |
| US20150030602A1 (en) * | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| AU2014255864B2 (en) * | 2013-04-15 | 2019-07-18 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
| US10011850B2 (en) | 2013-06-21 | 2018-07-03 | The General Hospital Corporation | Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| EP3110454B1 (en) | 2014-02-24 | 2020-11-18 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| FR3034420A1 (fr) * | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
-
2020
- 2020-06-12 IL IL288807A patent/IL288807B1/en unknown
- 2020-06-12 MX MX2021015057A patent/MX2021015057A/es unknown
- 2020-06-12 CA CA3138501A patent/CA3138501A1/en active Pending
- 2020-06-12 AU AU2020291939A patent/AU2020291939B2/en active Active
- 2020-06-12 CN CN202080043336.XA patent/CN113993891A/zh active Pending
- 2020-06-12 KR KR1020227000976A patent/KR102993101B1/ko active Active
- 2020-06-12 WO PCT/US2020/037589 patent/WO2020252381A2/en not_active Ceased
- 2020-06-12 BR BR112021025029A patent/BR112021025029A2/pt unknown
- 2020-06-12 JP JP2021573273A patent/JP7580406B2/ja active Active
- 2020-06-12 EP EP20823120.9A patent/EP3983435A4/en active Pending
- 2020-06-12 US US16/900,602 patent/US11781248B2/en active Active
- 2020-06-12 SG SG11202112553WA patent/SG11202112553WA/en unknown
-
2023
- 2023-07-18 US US18/354,037 patent/US20240003056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102993101B1 (ko) | 2026-07-20 |
| JP7580406B2 (ja) | 2024-11-11 |
| WO2020252381A2 (en) | 2020-12-17 |
| IL288807A (en) | 2022-02-01 |
| IL288807B1 (en) | 2026-08-01 |
| BR112021025029A2 (pt) | 2022-01-25 |
| EP3983435A4 (en) | 2023-03-08 |
| WO2020252381A3 (en) | 2021-03-11 |
| CA3138501A1 (en) | 2020-12-17 |
| US20200392252A1 (en) | 2020-12-17 |
| AU2020291939A1 (en) | 2021-12-02 |
| US20240003056A1 (en) | 2024-01-04 |
| US11781248B2 (en) | 2023-10-10 |
| JP2022536341A (ja) | 2022-08-15 |
| SG11202112553WA (en) | 2021-12-30 |
| KR20220020905A (ko) | 2022-02-21 |
| CN113993891A (zh) | 2022-01-28 |
| EP3983435A2 (en) | 2022-04-20 |
| AU2020291939B2 (en) | 2026-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124717T1 (el) | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων | |
| EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| MX2021003771A (es) | Analisis de analitos multiples usando un ensayo unico. | |
| MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| EA201591817A1 (ru) | Не содержащая сыворотки среда для культивирования клеток | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA202192126A3 (ru) | Способы сбора культур клеток млекопитающих | |
| WO2016172454A8 (en) | Microfluidic cell culture | |
| BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
| CL2017002604A1 (es) | Sondas duales silenciadoras | |
| CY1125242T1 (el) | Κυτταροκαλλιεργεια | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| BR112018071519A2 (pt) | técnicas para avaliação comparativa de estratégias de pareamento em um sistema de centro de contato | |
| AR100367A1 (es) | Anticuerpos biespecíficos químicamente bloqueados | |
| CR20200404A (es) | Anticuerpos anti-klk5 y métodos de uso | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX2017013620A (es) | PARTíCULAS DE PROTEíNA POROSAS COMO PORTADORAS PARA ACTIVOS. | |
| CO2022009691A2 (es) | Formulaciones líquidas de tasimelteón y métodos para su uso | |
| MX2024004106A (es) | Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra. | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| CL2017003309A1 (es) | Métodos de purificación y/o inactivación viral |